A research has evaluated the cardiotoxic effects of meglumine antimoniate for 60 days at therapeutic dosage in dogs with leishmaniasis, and it revealed that there was no demonstration in cTnI dosage or electrocardiographic characteristics of cardiac damage (61). This evidence concerns the gene TNNI3 and leishmaniasis.